Skip to content

Effectiveness of Cervical Transforaminal Epidural Steroid Injection

The Effectiveness of Cervical Transforaminal Epidural Steroid Injection for the Treatment of Cervical Radicular Pain: A Prospective Cohort Study.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04544683
Enrollment
33
Registered
2020-09-10
Start date
2018-10-23
Completion date
2023-12-07
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Radiculopathy, Cervical Spondylosis, Disk, Herniated

Keywords

Transforaminal Epidural Injection

Brief summary

Study Purpose: This study is intended to monitor outcomes for 1 year following cervical TFESI. Based on current clinic volume and enrollment rates into a current study of cervical epidural injections that is nearing completion, we conservatively estimate a study enrollment period of 18 months and a total period of 2.5 years from enrollment to final follow-up data collection. If the study were to theoretically start enrolling in July 2019, we would anticipate completion by February 2022. Objectives: 1. Determine the proportion of patients with an 80% or greater improvement in arm and neck numerical rating scale pain (NRS) score following an initial cervical transforaminal steroid injection (TFESI) at 4 weeks post-injection and the duration of response up to 12 months. 2. Determine the proportion of patients with a 50%-79% improvement in arm and neck NRS score following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 3. Determine the proportion of patients with less than 50% improvement in arm and neck NRS score following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 4. Determine the proportion of patients with an initial injection plus up to 3 additional injections that maintain 80% or greater, as well as 50-79%, improvement in arm and neck NRS score for up to 12 months. 5. Determine the proportion of patients with a clinically significant change in function defined by a minimally clinically significant change (MCIC) (≥10 point improvement ) or 30% improvement in Neck Disability Index (NDI) score following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 6. Determine the proportion of patients with clinically significant improvement in the Medication Quantification Scale (MQS III) score (≥6.8 point change , equivalent to 10 oral morphine equivalents ) following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 6\. Determine the proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) defined by ≥0.03 following an initial cervical TFESI at 4 weeks post-injection and the duration of response up to 12 months. 7\. Compare patient demographic, clinical, and imaging characteristics between response groups and perform predictive modeling to better understand variables that increase the likelihood of a successful clinical outcome. 8\. Report adverse effects.

Detailed description

Background and Project Justification: Neck pain is now the fourth leading cause of years lost to disability, shortly after back pain, depression, and arthralgia. Cervical radiculopathy, a common cause of neck and radiating arm pain, is estimated to afflict 83:100,000 individuals yearly. Age-related cervical spondylosis and disc herniation are the most common causes, with the C6 and C7 nerve roots most frequently affected. In general, patients who experience new onset radicular pain tend to improve within 4-6 months, with complete recovery in over 80% of patients by 24-36 months. However, a significant proportion of patients experience severe pain and associated functional impairment despite conservative care, which often prompts physician directed interventions. Cervical transforaminal epidural steroid injection (TFESI) is a target-specific treatment for refractory radicular pain. Analgesic mechanisms for epidural steroid administration include reducing inflammation at the nerve root, reducing nociceptive input from somatic nerves, stabilization of neural membranes, and blockade of C fiber activity in the dorsal root ganglion . Previously, this procedure was associated with rare but catastrophic neurologic injury, though to be related to inadvertent deposit of particulate steroid into the vertebral artery or radiculomedullary arteries, both of which traverse through or close to the cervical neuroforamina . Since the physician community has adopted new guidelines that include the use of only non-particulate steroid during cervical TFESI , neurologic infarction has not been reported in the literature. When the Spine Intervention Society (SIS) clinical practice guidelines are employed, large cohort study demonstrates zero prevalence of serious complications associated with this procedure . While high-quality outcome literature demonstrates both efficacy and effectiveness for analogous use of this intervention in the lumbar spine, far fewer studies have addressed clinical outcomes associated with cervical TFESI in which appropriate procedure technique , outcome measurement, data analysis, and results interpretation have been reported . Outcome literature reporting on the use of cervical TFESI is limited by small sample size, retrospective design with loss of follow-up, lack of categorical data analysis, and a failure to stratify results by demographic and clinical variables that potentially influence pain and functional outcomes. Further, outcome literature reports on the effect of particulate steroid injectate during cervical TFESI is no longer relevant to appropriate clinical practice in the context of unequivocal guidelines. Pragmatic studies with a cervical TFESI arm in which dexamethasone was use do allow for some insight regarding success rates associated with this procedure; calculates of success rates in these studies arms demonstrate responder rates of 60% achieving \>50% pain relief (CI95 35-85%) at 4 weeks, 55% achieving \>50% (CI95 43-67%) at 8 weeks, and 65% achieving \>50% at 12 weeks (CI95 48-81%). These responder rates are encouraging, but limited by wide 95% confidence intervals due to small sample size. Prior systematic review has concluded that the evidence for treatment benefit of radicular pain by cervical TFESI is of very low quality due to multiple limitations in study design introducing risk of bias, but does overall suggest approximately 50% patients experience 50% relief of radicular pain for at least 4 weeks after cervical TFESI. Additional clinical outcome literature is needed, particularly given recent policy decisions, such as that of Oregon State in relation to ending coverage of epidural steroid injections at any spinal level. Without expansion of the evidence-basis for this important procedure, there is a risk that this treatment option may be taken away from patients suffering from cervical radicular pain by further policy change. A sham-controlled trial, similar to the Ghahreman study, would be ideal; however, due to cost considerations germane to a study designed and conducted in a manner that would prevent any possible criticism from the larger medical community, we instead propose a high-quality, large prospective cohort study as a significant contribution to the literature. Even the best designed trials, such as Dreyfuss' 2006 study, have been underpowered to definitively demonstrate effectiveness; notably, the lower bound of the 95% confidence interval of the proportion of treatment responders in this study was 35%. The investigators aim to conduct a large enough cohort study narrow the 95% confidence interval of the proportion of responders substantially. Preliminary data from our center demonstrates a responder rate of 55% at 4-week follow-up (n=22), based on a definition of ≥50% improvement in index pain (Appendix A). These data represent analysis of consecutive patients who underwent cervical TFESI for unilateral radicular pain as a part of a different prospective outcome study at our center, nearing completion. This responder rate represents a conservative estimate of what might be expected in the proposed work, as the current study includes less stringent inclusion and exclusion criteria. Further, the investigators intend to use the results of this study as foundational data from which to propose a randomized controlled study through a large federal funding mechanism. It is imperative that such a trial be conducted by investigators who are experienced with this procedure and understand the appropriate standards for the design and interpretation of the results of a study of a treatment intervention for pain. Our spine research group is well-positioned for this, and we absolutely welcome the input and mentorship of the Spine Intervention Society Research Division, Board of Directors, and other leadership towards this mutual goal.

Interventions

DRUGCervical Transforaminal Epidural Injection with dexamethasone sodium phosphate

Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Through a research questionnaire, pre-procedure and post procedure NRS pain score for both neck and arm we will obtain data regarding cervical epidural steroid injections via a transforaminal approach for research purposes only. Also current pain medications of patient throughout treatment will be obtained for research purposes.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 18-80 capable of understanding and providing consent in English and capable of complying with the outcome instruments used. * Arm pain or shoulder girdle pain/periscapular pain with or without neck pain with duration less than or equal to 6 months. * 3-day average numeric pain rating score (NRS) for arm pain or shoulder girdle/periscapular pain of at least 4/10 at baseline evaluation, with neck pain score not exceeding arm and/or shoulder girdle/periscapular pain score. * MRI (or CT if MRI not available) shows either a one level cervical disc herniation, disc osteophyte complex or degenerative foraminal stenosis, corresponding in side and location with predominately unilateral radicular pain, with or without neurological deficits. MRI may show degenerative changes at other levels. * Patient consents to treatment with epidural injection in a shared decision-making process with the treating physician. * Pain duration of at least 6 weeks or more.

Exclusion criteria

* Those receiving remuneration for their pain treatment (e.g., disability, worker's compensation). * Those involved in active litigation relevant to their pain. * The patient is incarcerated. * Neck pain is greater than arm pain or shoulder girdle/periscapular pain. * Bilateral radicular signs/symptoms (\< 90% laterality of pain intensity, or bilateral neurological signs). * BMI\>35. * Prior epidural steroid injections for treatment of current episode. * Those unable to read English and complete the assessment instruments. * Spondylolisthesis at the involved or adjacent segments. * Systemic inflammatory arthritis (e.g., rheumatoid, lupus). * Addictive behavior, severe clinical depression, or psychotic features. * Possible pregnancy or other reason that precludes the use of fluoroscopy. * Treatment of infection with antibiotics within the past 7 days. * Progressive motor deficit and/or clinical signs of myelopathy. * History of prior cervical spine surgery. * Medical conditions causing significant functional disability (e.g., stroke, COPD)

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score1 month, 3 months, 6 months, 12 monthsPercentage of participants reporting 50% or greater improvement in index arm pain following an initial cervical transforaminal injection of steroid (CTFESI) at 1, 3, 6, and 12 months post-injection. Patient-reported arm pain intensity scores were captured at baseline and the designated follow-up time points using an 11-point Numeric Rating Scale ranging from 0 to 10, with 0 representing no pain at all and 10 representing the worst pain imaginable.

Secondary

MeasureTime frameDescription
The Number of Participants With a ≥30% Improvement in Neck Disability Index (NDI-5)1 month, 3 months, 6 months, 12 monthsThe 5-Item Neck Disability Index (NDI-5) is an assessment tool measuring patients' self-reported functional limitations due to neck pain. The range of possible scores is 0 to 24, with higher scores indicating greater functional impairment in activities of daily living.
The Number of Participants With a ≥0.03 Point Increase in EuroQol Health-Related Quality of Life (EQ-5D) Score1 month, 3 months, 6 months, 12 monthsThe EuroQol Health-Related Quality of Life 5-Dimension (EQ-5D) is an instrument used in clinical and research settings to assess overall quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are reported as an index ranging from 0 to 1, where 0 represents death and 1 represents perfect health.
The Number of Participants With a ≥6.8 Point Change in Medication Quantification Scale (MQS-III) Score1 month, 3 months, 6 months, 12 monthsThe Medication Quantification Scale (MQS) III is used to objectively quantify and monitor pain medication use (including opioid and non-opioid medications) in chronic pain populations. The lowest possible MQS III score is 0, indicating no current usage of any analgesic drugs assessed by this instrument. It is not possible to define a maximum score value because no theoretical upper limit exists. However, higher scores reflect greater negative impacts of a pain medication regimen, and a score of 6.8 points on the MQS III is comparable to 10 daily morphine equivalents in milligrams.
Percentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Neck Pain Score1 month, 3 months, 6 months, 12 monthsPercentage of participants reporting 50% or greater improvement in index neck pain following an initial cervical transforaminal injection of steroid (CTFESI) at 1, 3, 6, and 12 months post-injection. Patient-reported arm pain intensity scores were captured at baseline and the designated follow-up time points using an 11-point Numeric Rating Scale ranging from 0 to 10, with 0 representing no pain at all and 10 representing the worst pain imaginable.
Participant Improvement in Ability to Accomplish ≥3 Key Activities From Clinical Outcome Measurement Brief Instrument (COMBI)1 month, 3 months, 6 months, 12 monthsA measure of how many participants indicated an improvement in their ability to accomplish 4 key activities: driving, exercising, sleeping and sitting.
≥6 Patient Global Impression of Change (PGIC) Score1 month, 3 months, 6 months, 12 monthsPatient Global Impression of Change is a 7-point scale measuring participant reported satisfaction after an intervention. The outcome was measured as the percent of patients reporting a PGIC score of 6-7 (indicating much improved and very much improved).
The Number of Participants With a ≥30% Change in Chronic Pain Sleep Inventory (CPSI) Score1 month, 3 months, 6 months, 12 monthsThe Chronic Pain Sleep Inventory (CPSI) is an instrument used to assess the extent to which pain interferes with sleep quality in chronic pain populations. Scores range from 0 to 100, with higher values indicating greater levels of pain-mediated sleep interference.

Countries

United States

Participant flow

Participants by arm

ArmCount
Cervical Pain for 6 Months or Less and Scheduled for TFESI
Consenting participants who met eligibility criteria were enrolled into the study. The baseline examination and all baseline questionnaires were completed within 2 weeks before the first cervical TFESI. All follow-up measures were obtained at routine scheduled follow-up by clinic visit or telephone occurred at 1 month (+/- 1 week), 3 months (+/- 2 weeks), 6 months (+/- 1 month), and 12 months (+/- 1 month). Cervical Transforaminal Epidural Injection with dexamethasone sodium phosphate: Transforaminal epidural steroid injection: Injection of 1 to 2 mL of 1% lidocaine to the skin and subcutaneous tissues, a 25-gauge spinal needle will be placed at the level and side of radicular pathology, based on clinical correlation of symptoms/signs and magnetic resonance imaging findings. Advancement to the appropriate target position in the neuroforamen will be performed under fluoroscopic guidance. Satisfactory target position achieved and confirmed in both anterior-posterior and oblique views, 0.5 to 1 mL of contrast will be injected under live fluoroscopic observation with or without digital subtraction angiography depending on suggestion of vascular uptake. Upon confirmation of a satisfactory epidural contrast pattern without vascular uptake, the injectate will be delivered: dexamethasone sodium phosphate 1mL (10mg/mL) and 0.5 ml of 1% preservative-free lidocaine (total volume 1.5 mL).
33
Total33

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up2
Overall StudyUnderwent cervical spine surgery6

Baseline characteristics

CharacteristicCervical Pain for 6 Months or Less and Scheduled for TFESI
Affected Cervical Spinal Nerve Root Levels
C4
No
33 Participants
Affected Cervical Spinal Nerve Root Levels
C4
Yes
0 Participants
Affected Cervical Spinal Nerve Root Levels
C5
No
33 Participants
Affected Cervical Spinal Nerve Root Levels
C5
Yes
0 Participants
Affected Cervical Spinal Nerve Root Levels
C6
No
15 Participants
Affected Cervical Spinal Nerve Root Levels
C6
Yes
18 Participants
Affected Cervical Spinal Nerve Root Levels
C7
No
19 Participants
Affected Cervical Spinal Nerve Root Levels
C7
Yes
14 Participants
Affected Cervical Spinal Nerve Root Levels
C8
No
32 Participants
Affected Cervical Spinal Nerve Root Levels
C8
Yes
1 Participants
Age, Continuous51.2 years
STANDARD_DEVIATION 12.2
Arm Pain Numeric Rating Scale6.5 units on a scale
STANDARD_DEVIATION 1.4
Cervical Disc Herniation on MRI
No
22 Participants
Cervical Disc Herniation on MRI
Yes
11 Participants
Cervical Disc-Osteophyte Complex on MRI
No
18 Participants
Cervical Disc-Osteophyte Complex on MRI
Yes
15 Participants
Cervical Foraminal Stenosis Related to Bony Elements on MRI
No
24 Participants
Cervical Foraminal Stenosis Related to Bony Elements on MRI
Yes
9 Participants
Chronic Pain Sleep Inventory (CPSI)51.9 units on a scale
STANDARD_DEVIATION 30.7
Duration of Pain
>3 months up to 6 months
20 Participants
Duration of Pain
6 weeks to 3 months
13 Participants
EuroQol Health-Related Quality of Life (EQ-5D)0.61 units on a scale
STANDARD_DEVIATION 0.17
Foraminal Stenosis Severity (Park Classification)
Grade 0 or 1
9 Participants
Foraminal Stenosis Severity (Park Classification)
Grade 2
7 Participants
Foraminal Stenosis Severity (Park Classification)
Grade 3
17 Participants
History of Anxiety
No
26 Participants
History of Anxiety
Yes
7 Participants
History of Depression
No
24 Participants
History of Depression
Yes
9 Participants
Medication Quantification Scale (MQS) III Score6.0 units on a scale
STANDARD_DEVIATION 4.8
Neck Disability Index (NDI-5)9.4 units on a scale
STANDARD_DEVIATION 3.9
Neck Pain Numeric Rating Scale4.5 units on a scale
STANDARD_DEVIATION 2.9
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
21 Participants
Sex: Female, Male
Male
12 Participants
Tobacco Use
Current tobacco use
No
31 Participants
Tobacco Use
Current tobacco use
Yes
2 Participants
Tobacco Use
History of tobacco use
No
30 Participants
Tobacco Use
History of tobacco use
Yes
3 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 33
other
Total, other adverse events
0 / 33
serious
Total, serious adverse events
0 / 33

Outcome results

Primary

Percentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score

Percentage of participants reporting 50% or greater improvement in index arm pain following an initial cervical transforaminal injection of steroid (CTFESI) at 1, 3, 6, and 12 months post-injection. Patient-reported arm pain intensity scores were captured at baseline and the designated follow-up time points using an 11-point Numeric Rating Scale ranging from 0 to 10, with 0 representing no pain at all and 10 representing the worst pain imaginable.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score1 month19 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score3 months23 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score6 months20 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score12 months20 Participants
Secondary

≥6 Patient Global Impression of Change (PGIC) Score

Patient Global Impression of Change is a 7-point scale measuring participant reported satisfaction after an intervention. The outcome was measured as the percent of patients reporting a PGIC score of 6-7 (indicating much improved and very much improved).

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESI≥6 Patient Global Impression of Change (PGIC) Score1 month18 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESI≥6 Patient Global Impression of Change (PGIC) Score3 months21 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESI≥6 Patient Global Impression of Change (PGIC) Score6 months15 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESI≥6 Patient Global Impression of Change (PGIC) Score12 months18 Participants
Secondary

Participant Improvement in Ability to Accomplish ≥3 Key Activities From Clinical Outcome Measurement Brief Instrument (COMBI)

A measure of how many participants indicated an improvement in their ability to accomplish 4 key activities: driving, exercising, sleeping and sitting.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIParticipant Improvement in Ability to Accomplish ≥3 Key Activities From Clinical Outcome Measurement Brief Instrument (COMBI)1 month11 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIParticipant Improvement in Ability to Accomplish ≥3 Key Activities From Clinical Outcome Measurement Brief Instrument (COMBI)3 months18 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIParticipant Improvement in Ability to Accomplish ≥3 Key Activities From Clinical Outcome Measurement Brief Instrument (COMBI)6 months14 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIParticipant Improvement in Ability to Accomplish ≥3 Key Activities From Clinical Outcome Measurement Brief Instrument (COMBI)12 months16 Participants
Secondary

Percentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Neck Pain Score

Percentage of participants reporting 50% or greater improvement in index neck pain following an initial cervical transforaminal injection of steroid (CTFESI) at 1, 3, 6, and 12 months post-injection. Patient-reported arm pain intensity scores were captured at baseline and the designated follow-up time points using an 11-point Numeric Rating Scale ranging from 0 to 10, with 0 representing no pain at all and 10 representing the worst pain imaginable.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Neck Pain Score1 month11 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Neck Pain Score3 months14 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Neck Pain Score6 months9 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIPercentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Neck Pain Score12 months13 Participants
Secondary

The Number of Participants With a ≥0.03 Point Increase in EuroQol Health-Related Quality of Life (EQ-5D) Score

The EuroQol Health-Related Quality of Life 5-Dimension (EQ-5D) is an instrument used in clinical and research settings to assess overall quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Scores are reported as an index ranging from 0 to 1, where 0 represents death and 1 represents perfect health.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥0.03 Point Increase in EuroQol Health-Related Quality of Life (EQ-5D) Score1 month25 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥0.03 Point Increase in EuroQol Health-Related Quality of Life (EQ-5D) Score3 months25 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥0.03 Point Increase in EuroQol Health-Related Quality of Life (EQ-5D) Score6 months19 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥0.03 Point Increase in EuroQol Health-Related Quality of Life (EQ-5D) Score12 months23 Participants
Secondary

The Number of Participants With a ≥30% Change in Chronic Pain Sleep Inventory (CPSI) Score

The Chronic Pain Sleep Inventory (CPSI) is an instrument used to assess the extent to which pain interferes with sleep quality in chronic pain populations. Scores range from 0 to 100, with higher values indicating greater levels of pain-mediated sleep interference.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Change in Chronic Pain Sleep Inventory (CPSI) Score1 month9 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Change in Chronic Pain Sleep Inventory (CPSI) Score3 months12 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Change in Chronic Pain Sleep Inventory (CPSI) Score6 months5 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Change in Chronic Pain Sleep Inventory (CPSI) Score12 months7 Participants
Secondary

The Number of Participants With a ≥30% Improvement in Neck Disability Index (NDI-5)

The 5-Item Neck Disability Index (NDI-5) is an assessment tool measuring patients' self-reported functional limitations due to neck pain. The range of possible scores is 0 to 24, with higher scores indicating greater functional impairment in activities of daily living.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Improvement in Neck Disability Index (NDI-5)1 month20 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Improvement in Neck Disability Index (NDI-5)3 months22 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Improvement in Neck Disability Index (NDI-5)6 months19 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥30% Improvement in Neck Disability Index (NDI-5)12 months22 Participants
Secondary

The Number of Participants With a ≥6.8 Point Change in Medication Quantification Scale (MQS-III) Score

The Medication Quantification Scale (MQS) III is used to objectively quantify and monitor pain medication use (including opioid and non-opioid medications) in chronic pain populations. The lowest possible MQS III score is 0, indicating no current usage of any analgesic drugs assessed by this instrument. It is not possible to define a maximum score value because no theoretical upper limit exists. However, higher scores reflect greater negative impacts of a pain medication regimen, and a score of 6.8 points on the MQS III is comparable to 10 daily morphine equivalents in milligrams.

Time frame: 1 month, 3 months, 6 months, 12 months

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥6.8 Point Change in Medication Quantification Scale (MQS-III) Score1 month4 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥6.8 Point Change in Medication Quantification Scale (MQS-III) Score3 months4 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥6.8 Point Change in Medication Quantification Scale (MQS-III) Score6 months6 Participants
Cervical Pain for 6 Months or Less and Scheduled for TFESIThe Number of Participants With a ≥6.8 Point Change in Medication Quantification Scale (MQS-III) Score12 months6 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026